Fluticasone Furoate
| Evidence Level: L3 | Predicted Indications: 8 |
Table of Contents
Fluticasone Furoate: From Asthma/Allergic Rhinitis to Atopic Eczema
One-Sentence Summary
Fluticasone furoate is a long-acting inhaled/intranasal corticosteroid known for its approved use in asthma, COPD, and allergic rhinitis (marketed elsewhere as Veramyst and, combined with vilanterol, as Relvar/Breo Ellipta); it is not currently marketed in this jurisdiction. The TxGNN model predicts it may be effective for Atopic Eczema, with 11 clinical trials and 2 publications currently identified — though nearly all of this evidence involves the related ester fluticasone propionate rather than furoate itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available locally — drug is unlicensed in this jurisdiction (no label data); globally known for asthma/COPD/allergic rhinitis |
| Predicted New Indication | Atopic Eczema |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L3 |
| Market Status | Not marketed (Not Marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for fluticasone furoate is currently a data gap. Based on known pharmacological class information, fluticasone furoate is a synthetic glucocorticoid; its efficacy in asthma and COPD (in fixed combination with vilanterol) has been established, and mechanistically its anti-inflammatory action — suppression of pro-inflammatory cytokines and immune cell activation — is directly applicable to inflammatory skin conditions such as atopic eczema.
The predicted link is strengthened by the fact that a closely related ester, fluticasone propionate, is already an approved and widely used topical treatment for atopic dermatitis (e.g., Cutivate). Both molecules share the same corticosteroid core structure and differ only in their ester side chain, which primarily affects potency, lipophilicity, and duration of action rather than the underlying anti-inflammatory mechanism.
However, this is an important caveat: fluticasone furoate currently has no marketed topical/dermatological formulation, and essentially all of the identified clinical evidence for atopic eczema involves fluticasone propionate or third-party comparator drugs (tacrolimus, pimecrolimus, probiotics). Direct evidence for furoate itself in this indication is therefore indirect, and formulation development would likely be required before furoate could be studied topically.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03594565 | Early Phase 1 | Completed | 13 | Topical nasal steroids used for skin reactions to glucose monitoring devices in children with T1DM; small case series, not a primary AD trial |
| NCT01772056 | Phase 3 | Terminated | 54 | Twice-weekly fluticasone propionate maintenance cream reduced relapse risk in mild-to-moderate pediatric AD |
| NCT00546000 | Phase 4 | Completed | 56 | Evaluated HPA-axis suppression risk of fluticasone propionate (Cutivate) lotion in pediatric AD |
| NCT01915914 | Phase 4 | Completed | 107 | Intermittent fluticasone propionate cream plus daily moisturizer reduced relapse vs. moisturizer alone in stabilized pediatric AD |
| NCT04706559 | N/A | Completed | 98 | Oral probiotics in pediatric AD assessed via SCORAD index; mechanism unrelated to corticosteroids |
| NCT00690105 | Phase 4 | Completed | 577 | Tacrolimus 0.1% vs. fluticasone 0.005% ointment in adults with facial (“red face”) AD lesions |
| NCT03742414 | Phase 2 | Active, not recruiting | 398 | Proactive fluticasone propionate cream + barrier cream (Epiceram) to prevent AD progression and food allergy in infants |
| NCT00426283 | Phase 2 | Completed | 42 | Swallowed fluticasone propionate vs. placebo for eosinophilic esophagitis — off-target indication, not AD |
| NCT00689832 | Phase 4 | Completed | 487 | Tacrolimus 0.03% vs. fluticasone 0.005% ointment in children ≥2 years with moderate-severe AD |
| NCT00616538 | Phase 4 | Completed | 121 | Epiceram barrier-repair cream vs. mid-strength fluticasone propionate steroid in pediatric AD |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 19571596 | 2009 | Review | Neuroimmunomodulation | Reviews HPA-axis/adrenal suppression risk from intranasal corticosteroids in allergic conditions that commonly coexist with atopic dermatitis |
| 40066386 | 2025 | Case Report | Indian Journal of Otolaryngology and Head & Neck Surgery | Case study of allergen immunotherapy in a patient with autoimmune disease; notes atopic dermatitis as one application area of allergen-directed immunotherapy |
Market Information
No registrations found. This drug is currently not marketed in this jurisdiction (0 licenses on record), so no local product/dosage-form data is available.
Safety Considerations
Please refer to the package insert for safety information. (No local label warnings, contraindications, or drug interaction data were retrievable — this is flagged as a Blocking data gap for safety assessment.)
Conclusion and Next Steps
Decision: Research Question
Rationale: The mechanistic rationale is reasonable (corticosteroid class, shared core structure with the already-approved fluticasone propionate for AD), but nearly all supporting clinical evidence involves a different ester of fluticasone rather than furoate itself, and furoate currently has no topical formulation. Combined with the missing local safety label (blocking gap) and missing detailed MOA data, evidence is insufficient to move beyond a research question at this stage.
To proceed, the following is needed:
- Local product label data (warnings/contraindications) — currently a blocking data gap
- Detailed mechanism-of-action data for fluticasone furoate specifically
- Furoate-specific (not propionate) topical formulation development and preclinical/clinical bridging data
- Direct clinical trials of fluticasone furoate in atopic eczema/dermatitis
Note: Among this drug’s other predicted indications, bronchitis/COPD (rank 2) shows substantially stronger evidence — L1 evidence level, 28 trials including direct fluticasone furoate/vilanterol (Relvar/Breo Ellipta) studies, and a “Proceed with Guardrails” recommendation — since this reflects an indication already approved in other markets rather than a novel mechanistic hypothesis. That pathway may warrant higher near-term priority than the eczema indication covered in this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.